“Pfizer Inc.’s vaccine to protect newborns from RSV received backing from U.S. regulatory advisers for use in pregnant mothers to protect their newborns, handing the drugmaker a win in the race to dominate immunization against the virus.

All 14 members of the committee that advises the Food and Drug Administration recommended the vaccine as effective for use in pregnant women. In a separate question about safety, 10 panelists voted in favor of it and four voted against, saying they were concerned about pre-term births among participants. The FDA isn’t required to follow its advisers’ recommendations, but often does.”